For More Information Contact:
Angela D. Kendall
Executive Director, DKD Marketing
For Dermazone Solutions
+1-407-760-7360
akendall@dkdmarketing.com

Dermazone Solutions now holds permit to produce Prescription Drugs
Company meets stringent FDOH criteria and Pedigree Law requirements

Tampa/St. Petersburg, FL ***August 26, 2008****—Dermazone Solutions* announces the company's receipt of its Florida Department of Health permit to produce prescription drugs at its state-of-the-art St. Petersburg facility. Already a leader in over-the-counter (OTC) pharmaceuticals and cosmeceutical contract manufacturing, *Dermazone* can now provide formulating, manufacturing, and packaging services for prescription drugs. *Dermazone* met the Florida Statue ch. 499 requirements and pedigree law requirements by instituting comprehensive standard operating procedures (SOPs) and ensuring the facility is, at all times, working in compliance with F.S. ch. 499, which was designed to "safeguard the public health and promote the public welfare by protecting the public from injury by product use and merchandising deceit involving drugs devices and cosmetics." *Dermazone* developed these SOPs to cover a spectrum of requirements including meeting laboratory standards, transit and storage requirements, authentication requirements, labeling and advertising compliance requirements, and Pedigree process requirements.

"Florida is now leading the nation, having fully implemented in 2006 the state's stringent Pedigree laws. Few states even have Pedigree laws and of those that do, the laws are far less comprehensive than Florida's. Although these requirements drove many small-and-medium-size manufacturing companies out of the state, Dermazone Solutions chose to see this as a business opportunity. We believe that pharmaceutical sellers will embrace manufacturing pharmaceuticals under these very strict Pedigree policy and procedures. This will ensure them the finest quality product available in the U.S., a benefit they can pass to their consumers" says Deborah Duffey, *Dermazone's* President. According to Duffey, Florida has been particularly vigilant in developing stringent practices to avoid counterfeiting, a large problem in this state due to many ports and a large, potentially vulnerable senior population.

Dermazone anticipates that in the next two years, Rx manufacturing will be 60% of the company's manufacturing revenues. This rapid uptake will be made possible by the fact that the company has, to date, been providing OTC and cosmeceuticals already manufactured to Rx standards.

Dermazone Solutions, is the parent company of *dermaCM* and *Kara Vita* and offers more than 17 years in research and development of cutting-edge all-natural nanotechnologies at a facility that is one of the most advanced analytical, microbiological research and development laboratories in the industry. The company's focus in the Rx industry will initially be topical.

ABOUT Dermazone Solutions

Dermazone Solutions, Inc. is an acknowledged leader in the field of nanotechnology and holds patents on its proprietary nanosphere delivery systems. The company's state-of-the art manufacturing facility is FDA-registered and can offer a wide range of product services including formulating, private labeling, manufacturing, packaging and fulfillment for OTC pharmaceuticals, and cosmeceuticals. As of August 2008, prescription drug manufacturing and formulating is available. Dermazone is located in St. Petersburg, FL, U.S. For more information, visit www.dermazone.com.

###